Dallas, TX Clinical Trials Report — July 2026

Dallas residents should act quickly if they match a study closing soon: 71 recruiting trials are expected to close within the next 90 days, including 14 that accept healthy volunteers. Dallas currently has 1,464 recruiting trials across 665 research facilities, giving patients and volunteers a broad local selection while enrollment windows remain open.

July brought 27 new trials, down from 31 in May 2026. The city’s active research network spans academic medicine, cancer care, hospitals, specialty clinics, and community research sites. People who do not find a suitable Dallas study can also consider Houston, San Antonio, Austin, or Fort Worth.

Closing-soon studies create the most immediate opportunities

Enrollment deadlines can change if a study reaches its participant target early, so people with relevant diagnoses should contact study teams rather than waiting for the projected closing date. The conditions most represented among Dallas trials closing within 90 days are:

• Aging and hypertension (4 trials each)
• Renal cell carcinoma and prostate cancer (3 trials each)
• Obesity (3 trials)
• Non-small cell lung cancer and heart failure (2 trials each)
• Asthma and Duchenne muscular dystrophy (2 trials each)
• Healthy-volunteer studies (2 trials)

There are 14 closing-soon studies that accept healthy volunteers, while 120 healthy-volunteer trials are recruiting across Dallas overall. Requirements can include age ranges, medication restrictions, health screening, sex-specific criteria, and multiple study visits. Healthy adults interested in paid or non-treatment research should review these studies now because local availability may change quickly.

Major Phase 3 studies open in Dallas

Drug trials account for 18 of July’s new openings, followed by device studies and other research. The month includes several large Phase 3 studies sponsored by Novo Nordisk, AstraZeneca, Akeso, and Bristol-Myers Squibb. These trials address weight management and several serious cancers.

• NCT07720271 is Novo Nordisk’s Phase 3 AMAZE 9 study of once-daily zenagamtide tablets for people with excess body weight. The study plans to enroll 950 participants and compares zenagamtide with placebo.
• NCT07720284 is an AstraZeneca Phase 3 study comparing dato-DXd plus rilvegostomig with standard care for adults with high-risk muscle-invasive urothelial cancer after surgery. Planned enrollment is 915 participants.
• NCT07700979 is a Phase 3 Akeso study of cadonilimab combined with chemotherapy for previously untreated, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. The study expects 900 participants.
• NCT07680790 is Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study of izalontamab brengitecan with osimertinib for previously untreated EGFR-mutant non-small cell lung cancer. Planned enrollment is 850 participants.

Other new Dallas studies cover major depressive disorder, obesity, acute myeloid leukemia, broken endocardial leads, cannabis use disorder, chronic plaque psoriasis, cognitive control, food insecurity, cystic fibrosis, and type 2 diabetes. NCT07696338 examines early airway-clearance therapies for people with cystic fibrosis, while NCT07713836 studies nutrition interventions designed to better support people affected by food insecurity. These studies reflect a mixture of treatment, behavioral, nutrition, and supportive-care research.

UT Southwestern is Dallas’s largest research hub

The University of Texas Southwestern system accounts for the city’s deepest concentration of research activity. Several database listings use slightly different names for affiliated departments and locations, so people should check the exact site listed for each study before contacting a center.

• University of Texas Southwestern Medical Center (172 trials)
• UT Southwestern Medical Center (162 trials)
• UT Southwestern/Simmons Cancer Center-Dallas (89 trials)
• University of Texas Southwestern (57 trials)
• Research Site (43 trials)
• Baylor University Medical Center (38 trials)
• Parkland Memorial Hospital (33 trials)
• Medical City Dallas Hospital (28 trials)
• Mary Crowley Cancer Research (27 trials)
• UT Southwestern Simmons Cancer Center - RedBird (24 trials)
• The University of Texas Southwestern Medical Center (23 trials)
• Retina Foundation of the Southwest (20 trials)

UT Southwestern and its Simmons Cancer Center locations are particularly important starting points for oncology, while Baylor University Medical Center, Parkland, and Medical City Dallas provide additional hospital-based options. Retina Foundation of the Southwest offers a specialized setting for eye research. The largest sites also run studies in areas such as metabolic health, neurology, cardiovascular disease, and rare conditions.

Who can participate in July’s new studies?

Of the 27 new trials, 3 accept healthy volunteers. Six include children, one is female-only, and none is male-only. Twenty-one include older adults. The new-trial sponsor list is led by the University of Texas Southwestern Medical Center, which sponsors 9 openings. Other sponsors include Amgen, AstraZeneca, Baylor Research Institute, Biogen, Bristol-Myers Squibb, Eli Lilly and Company, and Evopoint Biosciences.

Academic and nonprofit activity remains prominent: 15 new trials are categorized as other, compared with 12 industry-sponsored studies. The study types include drug, device, behavioral, biological, radiation, and other research. People should confirm whether a trial provides treatment, evaluates a device or procedure, or involves observation and testing only.

Other Texas cities to consider

Dallas has more recruiting trials than the other listed Texas cities, but travel may expand the number of possible matches. Houston has 51 trials, followed by San Antonio with 17 and Austin with 12. Fort Worth has 7, Richardson has 5, and Edinburg has 3. Fort Sam Houston and El Paso each have 2.

New openings have declined from 40 in February and 42 in March to 27 in July, after reaching 39 in May and 31 in June. With closing deadlines approaching and 120 healthy-volunteer studies still recruiting, Dallas patients and volunteers should review eligibility and contact sites early as the second half of 2026 brings new enrollment changes.